FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280492067> ?p ?o ?g. }

• W4280492067 endingPage "A038" @default.
• W4280492067 startingPage "A038" @default.
• W4280492067 abstract "Abstract Tumorigenesis begins with cells that have normal mutation rates. As the cells become immortal and accumulate different numbers of mutations along the way, current literature splits in two describing if and how mutation rates increase as the cancer progresses. Some argue that as the mutation rates are small (mutation rate in healthy cells is per nucleotide site per cell division) and malignant cells are loaded with thousands of different types of mutations, they must have acquired a mutator phenotype early in their development. Others argue that immortality of malignant cells, and their rate of proliferation is responsible for their genetic instability and number of mutations observed in their genome. We conduct a review of the literature with the key words “mutation rate” and “cancer” in their title. We review 123 papers and found that description of mutation rates varied in the published work. This leads to estimates of mutation rates in cancer from per nucleotide site per cell division. Some of this variation in mutational rates arises across different organs of the body, for instance liver cells have a higher mutation rate than heart and brain. Cancer treatments such as chemotherapy influence mutation rate, and mutation rate of drug and multidrug resistance cancer cell is higher than newly diagnosed cancer cells. Further, mutation rate is defined differently in different literature, some papers measure the mutation rate in a population or a gene, some calculate it per base pair, genome, or mitosis. Here we provide a comprehensive picture of published mutation rates across different cancer types in order to inform cancer models and treatment plans for individual patients. We propose a unified framework for discussing and reporting mutation rate of cancer cells and formulations on how to switch between definitions. Citation Format: Fargam Neinavaie, Andrew Kramer. Does mutation rate of cancer cells change as the stage of the disease advances? [abstract]. In: Proceedings of the AACR Special Conference on the Evolutionary Dynamics in Carcinogenesis and Response to Therapy; 2022 Mar 14-17. Philadelphia (PA): AACR; Cancer Res 2022;82(10 Suppl):Abstract nr A038." @default.
• W4280492067 created "2022-05-22" @default.
• W4280492067 creator A5037770877 @default.
• W4280492067 creator A5056781712 @default.
• W4280492067 date "2022-05-15" @default.
• W4280492067 modified "2023-10-17" @default.
• W4280492067 title "Abstract A038: Does mutation rate of cancer cells change as the stage of the disease advances?" @default.
• W4280492067 doi "https://doi.org/10.1158/1538-7445.evodyn22-a038" @default.
• W4280492067 hasPublicationYear "2022" @default.
• W4280492067 type Work @default.
• W4280492067 citedByCount "0" @default.
• W4280492067 crossrefType "journal-article" @default.
• W4280492067 hasAuthorship W4280492067A5037770877 @default.
• W4280492067 hasAuthorship W4280492067A5056781712 @default.
• W4280492067 hasConcept C104317684 @default.
• W4280492067 hasConcept C121608353 @default.
• W4280492067 hasConcept C2908647359 @default.
• W4280492067 hasConcept C2910240311 @default.
• W4280492067 hasConcept C501734568 @default.
• W4280492067 hasConcept C502942594 @default.
• W4280492067 hasConcept C54355233 @default.
• W4280492067 hasConcept C555283112 @default.
• W4280492067 hasConcept C71924100 @default.
• W4280492067 hasConcept C86803240 @default.
• W4280492067 hasConcept C98638677 @default.
• W4280492067 hasConcept C99454951 @default.
• W4280492067 hasConceptScore W4280492067C104317684 @default.
• W4280492067 hasConceptScore W4280492067C121608353 @default.
• W4280492067 hasConceptScore W4280492067C2908647359 @default.
• W4280492067 hasConceptScore W4280492067C2910240311 @default.
• W4280492067 hasConceptScore W4280492067C501734568 @default.
• W4280492067 hasConceptScore W4280492067C502942594 @default.
• W4280492067 hasConceptScore W4280492067C54355233 @default.
• W4280492067 hasConceptScore W4280492067C555283112 @default.
• W4280492067 hasConceptScore W4280492067C71924100 @default.
• W4280492067 hasConceptScore W4280492067C86803240 @default.
• W4280492067 hasConceptScore W4280492067C98638677 @default.
• W4280492067 hasConceptScore W4280492067C99454951 @default.
• W4280492067 hasIssue "10_Supplement" @default.
• W4280492067 hasLocation W42804920671 @default.
• W4280492067 hasOpenAccess W4280492067 @default.
• W4280492067 hasPrimaryLocation W42804920671 @default.
• W4280492067 hasRelatedWork W1911318042 @default.
• W4280492067 hasRelatedWork W1958991600 @default.
• W4280492067 hasRelatedWork W1980121199 @default.
• W4280492067 hasRelatedWork W2024289194 @default.
• W4280492067 hasRelatedWork W2110451776 @default.
• W4280492067 hasRelatedWork W2135108461 @default.
• W4280492067 hasRelatedWork W2146849562 @default.
• W4280492067 hasRelatedWork W2149943693 @default.
• W4280492067 hasRelatedWork W2170167044 @default.
• W4280492067 hasRelatedWork W2471617370 @default.
• W4280492067 hasVolume "82" @default.
• W4280492067 isParatext "false" @default.
• W4280492067 isRetracted "false" @default.
• W4280492067 workType "article" @default.